7 regulatory shifts accelerating pharmaceutical 3D printing adoption in 2026
The FDA's Center for Drug Evaluation and Research has issued three new guidance documents in Q1 2026 specifically addressing additive manufacturing quality metrics, signaling a decisive pivot toward standardized oversight for personalized therapeutics. This regulatory clarity arrives as European Medicines...